FDA Expands Use of Mylotarg to Infants at Least 1 Month Old

By SPC News Staff

The FDA extended the indication for gemtuzumab ozogamicin (Mylotarg, Wyeth) to treat newly diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older.